论文部分内容阅读
提高药物对肿瘤选择性的输送,是纳米医学领域这十多年来一直致力研究的课题。利用纳米粒子作为载体,可以提高抗肿瘤药物的安全性和治疗效果。目前,多种纳米制剂已通过临床批准,如多柔比星(DOXIL、Calyx和Myocet)、伊立替康(Onivyde)、紫杉醇(Abraxane)及长春新碱(Marqibo)等。然而,临床实验数据却不是那么让人乐观,纳米制剂中的大部分仍然未能到达肿瘤靶点。一个解决策略是利用具有亲和配体或是抗体对纳米粒子进行修饰,以此来主动靶向肿瘤细胞。然而,近来一项大数据分析显
To enhance the selective delivery of drugs to tumors is a subject that has been devoted to research for more than ten years in the field of nanomedicine. Use of nanoparticles as a carrier, can improve the safety of antineoplastic drugs and treatment. Currently, a variety of nano-formulations have passed clinical approval, such as doxorubicin (DOXIL, Calyx and Myocet), irinotecan (Onivyde), paclitaxel (Abraxane) and vincristine (Marqibo) and so on. However, the clinical trial data is not so optimistic that most of the nano-formulations still fail to reach the tumor targets. One solution is to actively target the tumor cells by modifying the nanoparticles with affinity ligands or antibodies. However, a big data analysis has been made recently